Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

My name is Chris Yu. I'm on Terrence Flynn's team covering biopharma and biotech companies. I'm delighted to host Allan Reine, CEO of Prime Medicine. Before we start, for important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. So, Allan, thank you for joining us. Allan Reine CEO & Director Thank you for having me here. Question-and-Answer Session Operator Maybe we start with some high-level questions about the company. In the past two decades, we have all witnessed the amazing evolution of gene editing technologies. And you guys are at the forefront of that. So maybe talk about how Prime Editing is different versus kind of the earlier generations of gene editing technologies. Allan Reine CEO & Director Yes, and I think you said it right. It really is a revolution. I think we're all very lucky to kind of, be alive to see these technologies and others as they advance. I know they're just incredible as you think of where we were 20 years ago and where we are today. So I always think about the evolution of CRISPR, kind of, nuclease-based editing kind of, to Prime Editing. And nuclease-based editing, we're looking at Nobel-winning technology, really incredible for the first time. You could, with very high efficiency, go to a very specific point in the DNA and with a double-stranded break really make that cut. And the result being very effective at knocking out targets, very effective at knocking out proteins or changing regulatory elements like they do in sickle cell, and an incredible technology. We have an approved drug now. We have others that are likely looking like